TY - JOUR
T1 - Development of transmucosal patch using nanofibers
AU - Grewal, Harleen
AU - Dhakate, Sanjay R.
AU - Goyal, Amit K.
AU - Markandeywar, Tanmay S.
AU - Malik, Basant
AU - Rath, Goutam
N1 - Generated from Scopus record by KAUST IRTS on 2023-10-12
PY - 2012/2/1
Y1 - 2012/2/1
N2 - In the present work we have attempted to develop a novel transmucosal patch of diclofenac sodium using electrospun polycaprolactone (PCL) nanofibers. PCL nanofibers were prepared by electrospinning techniques using different polymer concentrations. Nanofibers formulations were characterized by SEM, FTIR, drug loading, and in-vitro release study using Franz diffusion cell. Studies revealed the nanofibers fabricated from 13% PCL were fracture-free, non-beaded, and ultrafine with 120 nm diameter. Release studies demonstrated the sustained release behavior of PCL nanofibers. Nanofibers can be exploited for transmucosal drug delivery of NSAID with improved therapeutic efficacy. © 2012 Informa Healthcare USA, Inc.
AB - In the present work we have attempted to develop a novel transmucosal patch of diclofenac sodium using electrospun polycaprolactone (PCL) nanofibers. PCL nanofibers were prepared by electrospinning techniques using different polymer concentrations. Nanofibers formulations were characterized by SEM, FTIR, drug loading, and in-vitro release study using Franz diffusion cell. Studies revealed the nanofibers fabricated from 13% PCL were fracture-free, non-beaded, and ultrafine with 120 nm diameter. Release studies demonstrated the sustained release behavior of PCL nanofibers. Nanofibers can be exploited for transmucosal drug delivery of NSAID with improved therapeutic efficacy. © 2012 Informa Healthcare USA, Inc.
UR - http://www.tandfonline.com/doi/full/10.3109/10731199.2011.637924
UR - http://www.scopus.com/inward/record.url?scp=84856592906&partnerID=8YFLogxK
U2 - 10.3109/10731199.2011.637924
DO - 10.3109/10731199.2011.637924
M3 - Article
SN - 1073-1199
VL - 40
SP - 146
EP - 150
JO - Artificial Cells, Blood Substitutes, and Biotechnology
JF - Artificial Cells, Blood Substitutes, and Biotechnology
IS - 1-2
ER -